US District Court | GenomeWeb

US District Court

The US District Court in Delaware has adopted Enzo's interpretation of patent language and rejected the defendants' argument to invalidate a key patent.

NEW YORK (GenomeWeb) – The US District Court for the Middle District of North Carolina has denied a motion brought by GlaxoSmithKline that sought to dismiss a patent infringement suit Genetic Technologies had filed against the drug giant two year ago.

The story has been updated to include comments from Complete Genomics.
By a GenomeWeb staff reporter

Plaintiffs challenging one of Myriad's BRCA patents in the Australian federal court have applied to extend the scope of the case to include additional BRCA patents held by the company.

In an out-of-court settlement, Qiagen and Roche decided they both would have distribution rights to TheraScreen tests from Qiagen subsidiary DxS.

Myriad's stock took a hit on Tuesday after a federal District Court declared the firm's BRCA gene patents were invalid.

"DxS is seeking to avoid its exclusive obligation with Roche because it no longer finds it advantageous to benefit from the Roche distribution network," but a termination of the agreement would cause "irreparable" harm, Roche stated in a recently filed complaint.

Illumina claims that Affy's new GeneTitan platform infringes its array technology. A trial date has been set for Oct. 4, 2010.

The suit revolves around patents owned by UNeMed, the technology-transfer organization for the UN Medical Center, and exclusively licensed to Abbot Laboratories, though Abbott is not listed as a co-plaintiff on the complaint.

The study, begun last year, will take longer than the June 2009 timeframe projected late last year. It calls for the NIH to analyze the ability of the Biosafety Level 4 lab to contain 13 toxins to be studied there, and ensure it can run safely.

Pages

In PNAS this week: variation patterns in wheat lines, regulatory variation in Capsella grandiflora, and more.

A Rockefeller University researcher is using edited ants to explore complex biological systems, the New York Times writes.

There's a heritable aspect to how much time people spend online, the Los Angeles Times reports.

Stat News reports that Joseph Gulfo is another contender for FDA commissioner.